Mohsen Safaei

Dr. Mohsen Safaei

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Journal of Drug Targeting
Verified
Journal Article
Closed access
RHRazieh Heidari
Razieh Heidari
NDNeda Gholamian Dehkordi
Neda Gholamian Dehkordi
RMRoohollah Mohseni
Roohollah Mohseni
MSMohsen Safaei
Mohsen Safaei
Breast cancer is one of the most prevalent and deadliest cancers among women in the world because of its aggressive behavior and inadequate response to conventional therapies. Cellular and gene therapies based on mesenchymal stem cells (MSCs) represent promising treatment strategies for multiple diseases, such as cancers. MSCs are multipotent adult stem cells with important features for cell therapy, such as tissue homing to injured sites, their differentiation potential, their capacity of secreting plenty of trophic factors, and low immunogenicity. The quite easy isolation of these cells from various types of tissues are associated with no ethical concern when dealing with fetal or embryonic stem cells. The MSCs exhibit both pro and anti-oncogenic properties. However, genetic engineering of MSCs and nanoparticles is being employed as a means to solve some of these problems and improve the antitumor properties of these cells. The tumor-homing ability of MSCs and their exosomes to tumor niches have made them as a promising vector for targeted delivery of therapeutic agents to tumors site. The present study investigated MSCs specifications, pro- and anti-oncogenic properties of MSCs in breast cancer, and reviewed targeted breast cancer therapy via engineered MSCs, likely as potent cellular vehicles.

5 April 2023 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
ZAZahra Abpeikar
Zahra Abpeikar
AAAli Akbar Alizadeh
Ali Akbar Alizadeh
LRLeila Rezakhani
Leila Rezakhani
VRVahid Ramezani
Vahid Ramezani
AGArash Goodarzi
Arash Goodarzi
MSMohsen Safaei
Mohsen Safaei

1 October 2023 in Nanomedicine
Verified
Journal Article
Closed access
MSMohsen Safaei
Mohsen Safaei
FKFatemeh Khalighi
Fatemeh Khalighi
FBFatemeh Akhavan Behabadi
Fatemeh Akhavan Behabadi
ZAZahra Abpeikar
Zahra Abpeikar
AGArash Goodarzi
Arash Goodarzi
VRVahid Ramezani
Vahid Ramezani
This review discusses the application of nanoliposomes containing siRNA/drug to overcome multidrug resistance for all types of cancer treatments. As drug resistance-associated factors are overexpre... Graphical abstract

6 September 2022 in Regenerative Medicine
Verified
Journal Article
Closed access
ZAZahra Abpeikar
Zahra Abpeikar
AAAli Akbar Alizadeh
Ali Akbar Alizadeh
Mohammad AhmadyousefiMohammad Ahmadyousefi
Mohammad Ahmadyousefi
ANAli Akbar Najafi
Ali Akbar Najafi
MSMohsen Safaei
Mohsen Safaei
In this review, gene delivery and its applications are discussed in tissue engineering (TE); also, new techniques such as the CRISPR-Cas9 system, synthetics biology and molecular dynamics simulatio... TWEETABLE ABSTRACT Engineered cells and smart scaffolds for improving tissue engineering approaches. Graphical abstract

8 June 2026 in Journal of Polymers and the Environment
Verified
Journal Article
Closed access
PDF file
MSMohsen Safaei
Mohsen Safaei
FNFariba Noori
Fariba Noori
MJMozhgan Jirehnezhadyan
Mozhgan Jirehnezhadyan
MTMahtab Tirgar
Mahtab Tirgar
HJHamid Reza Ghaderi Jafarbeigloo
Hamid Reza Ghaderi Jafarbeigloo
ZAZahra Abpeikar
Zahra Abpeikar

1 August 2021 in Current Signal Transduction Therapy
Verified
Journal Article
Open access
PDF file
MSMohsen Safaei
Mohsen Safaei
AMAmeneh Mehri-Ghahfarrokhi
Ameneh Mehri-Ghahfarrokhi
ASAli Shojaeian
Ali Shojaeian
Background: Long non-coding ribonucleic acid (lncRNA) is known as similar transcripts of messenger RNA (mRNA) whose size discrepancy is between 100 and 200 nucleotides. Recent studies in this area have revealed that lncRNAs are involved in cancer tumorogenesis and progression. Such molecules are transcribed from genome regions that lack open reading frame (ORF) and fail to encode any protein. LncRNAs are characterized by tumorigenic behaviors which can be considered as new biomarkers. Among all types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is the most common one. Methods: This review was prepared via searching of the databases of Science Direct, Directory of Open Access Journals (DOAJ), Google Scholar, Pub-Med (NLM), Scopus, Web of Science, and hand searching using relative keywords. The selected papers were fully reviewed and required information for the review was extracted and summarized. Results: Pervious studies indicated that BRAF-activated non-protein coding RNA (BANCR) expression had been increased in thyroid tumors compared with adjacent normal tissues. Additionally, BANCR had mediated epithelial-mesenchymal transition (EMT) through regulating the expression of epithelial (E)-cadherin, vimentin, and neuronal (N)-cadherin. Moreover, H19 was an example of an lncRNA that could function either as a tumor promoter or suppressor. An important part of this study was dedicated to reviewing signaling pathways involved in TC including extracellular-signal-regulated kinase (ERK) pathway and mitogen-activated protein kinase (ERK/MAPK), transforming growth factor-β/ (TGF-ß)/Smads, the Janus kinase/signal transducers and activators of transcription (JAK/STAT), P53, as well as other pathways. Conclusion: Briefly, this study provided an overview on current understanding of the function of lncRNA and micro RNAs (miRNAs) along with their interactions in TC.